Nirav N Shah, MD | Medical College of Wisconsin

Nirav N. Shah, MD

Associate Professor

view physician profile

Locations

Froedtert Hospital
Cancer Center - Froedtert Hospital

Specialties

Hematology
Medical Oncology

Languages

English, Gujarati

Contact Information

(414) 805-0505

Education

MD - Doctor of Medicine

Biography

Nirav Shah, MD, MSHP, is Assistant Professor of Medicine at the Medical College of Wisconsin, Division of Hematology and Oncology, specializing in lymphoma, CAR-T cell therapy, and stem cell transplant at Froedtert Hospital. He graduated with honors and Alpha Omega Alpha Honor Society membership from the University of Illinois at Chicago College of Medicine in 2008. He then completed his Internal Medicine residency at Massachusetts General Hospital in Boston, Massachusetts in 2011. Post-residency, he took a position at Northwestern Memorial Hospital in Hospitalist medicine before proceeding to the University of Pennsylvania where he completed both hematology/oncology fellowship and a Master’s degree in Health Policy research in 2015.

Research Interests

Dr. Shah's current clinical and research interests include developing new cell based and immune therapies for patients with non-Hodgkin and Hodgkin lymphoma. He is specifically involved in the development of new CAR-T cell therapies for blood cancers. His professional memberships include the American Society of Hematology and the American Society of Clinical Oncology.

Dr. Shah is board certified by the American Board of Internal Medicine (ABIM) in Hematology, Medical Oncology, and Internal Medicine.

A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes.

(Nazha A, Hu ZH, Wang T, Lindsley RC, Abdel-Azim H, Aljurf M, Bacher U, Bashey A, Cahn JY, Cerny J, Copelan E, DeFilipp Z, Diaz MA, Farhadfar N, Gadalla SM, Gale RP, George B, Gergis U, Grunwald MR, Hamilton B, Hashmi S, Hildebrandt GC, Inamoto Y, Kalaycio M, Kamble RT, Kharfan-Dabaja MA, Lazarus HM, Liesveld JL, Litzow MR, Majhail NS, Murthy HS, Nathan S, Nishihori T, Pawarode A, Rizzieri D, Sabloff M, Savani BN, Schachter L, Schouten HC, Seo S, Shah NN, Solh M, Valcárcel D, Vij R, Warlick E, Wirk B, Wood WA, Yared JA, Alyea E, Popat U, Sobecks RM, Scott BL, Nakamura R, Saber W.) Biol Blood Marrow Transplant. 2020 Nov;26(11):2139-2146 PMID: 32781289 PMCID: PMC7609542 SCOPUS ID: 2-s2.0-85090061841 08/12/2020
Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation.

(Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Douglas Rizzo J, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M.) Biol Blood Marrow Transplant. 2020 Oct;26(10):1876-1885 PMID: 32653622 PMCID: PMC7571859 SCOPUS ID: 2-s2.0-85089134303 07/13/2020
Treatment-Emergent Tumor Lysis Syndrome With PI3Kδ-γ Inhibition After CAR T-Cell Therapy for Chronic Lymphocytic Leukemia.

(Shah NN, Jerkins JH, Johnson BD, Hari P.) JCO Oncol Pract. 2020 Sep;16(9):613-614 PMID: 32603254 SCOPUS ID: 2-s2.0-85090870606 07/01/2020
Severity of Cytokine Release Syndrome and Its Association with Infections after T Cell-Replete Haploidentical Related Donor Transplantation.

(Abid MB, Hamadani M, Szabo A, Hari PN, Graham MB, Frank MO, Collier WS, Abedin S, Jerkins JH, Pasquini MC, Runaas L, Shah NN, Chhabra S.) Biol Blood Marrow Transplant. 2020 Sep;26(9):1670-1678 PMID: 32562858 SCOPUS ID: 2-s2.0-85087739042 06/21/2020
Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents.

(Roeker LE, Dreger P, Brown JR, Lahoud OB, Eyre TA, Brander DM, Skarbnik A, Coombs CC, Kim HT, Davids M, Manchini ST, George G, Shah N, Voorhees TJ, Orchard KH, Walter HS, Arumainathan AK, Sitlinger A, Park JH, Geyer MB, Zelenetz AD, Sauter CS, Giralt SA, Perales MA, Mato AR.) Blood Adv. 2020 Aug 25;4(16):3977-3989 PMID: 32841336 PMCID: PMC7448605 SCOPUS ID: 2-s2.0-85090336061 08/26/2020
Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report.

(Zhou Z, Nath R, Cerny J, Wang HL, Zhang MJ, Abdel-Azim H, Agrawal V, Ahmed G, Al-Homsi AS, Aljurf M, Alkhateeb HB, Assal A, Bacher U, Bajel A, Bashir Q, Battiwalla M, Bhatt VR, Byrne M, Cahn JY, Cairo M, Choe H, Copelan E, Cutler C, Damlaj MB, DeFilipp Z, De Lima M, Diaz MA, Farhadfar N, Foran J, Freytes CO, Gerds AT, Gergis U, Grunwald MR, Gul Z, Hamadani M, Hashmi S, Hertzberg M, Hildebrandt GC, Hossain N, Inamoto Y, Isola L, Jain T, Kamble RT, Khan MW, Kharfan-Dabaja MA, Kebriaei P, Kekre N, Khera N, Lazarus HM, Liesveld JL, Litzow M, Liu H, Marks DI, Martino R, Mathews V, Mishra A, Murthy HS, Nagler A, Nakamura R, Nathan S, Nishihori T, Olin R, Olsson RF, Palmisiano N, Patel SS, Patnaik MM, Pawarode A, Perales MA, Politikos I, Popat U, Rizzieri D, Sandmaier BM, Savani BN, Seo S, Shah NN, Uy GL, Valcárcel D, Verdonck LF, Waller EK, Wang Y, Weisdorf D, Wirk B, Wong E, Yared JA, Saber W.) Blood Adv. 2020 Jul 14;4(13):3180-3190 PMID: 32663298 PMCID: PMC7362362 SCOPUS ID: 2-s2.0-85088320644 07/15/2020
Intrathecal chemotherapy for management of steroid-refractory CAR T-cell-associated neurotoxicity syndrome.

(Shah NN, Johnson BD, Fenske TS, Raj RV, Hari P.) Blood Adv. 2020 May 26;4(10):2119-2122 PMID: 32407473 PMCID: PMC7252557 SCOPUS ID: 2-s2.0-85086848668 05/15/2020
Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial.

(Jagasia M, Perales MA, Schroeder MA, Ali H, Shah NN, Chen YB, Fazal S, Dawkins FW, Arbushites MC, Tian C, Connelly-Smith L, Howell MD, Khoury HJ.) Blood. 2020 May 14;135(20):1739-1749 PMID: 32160294 PMCID: PMC7229262 SCOPUS ID: 2-s2.0-85083637011 03/12/2020
Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes.

(Chhabra S, Narra RK, Wu R, Szabo A, George G, Michaelis LC, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Pasquini MC, Rizzo RD, Saber W, Shah NN, Shaw BE, Hamadani M, Hari PN.) Biol Blood Marrow Transplant. 2020 May;26(5):893-901 PMID: 31982543 SCOPUS ID: 2-s2.0-85080146585 01/27/2020
Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial.

(Knight JM, Rizzo JD, Hari P, Pasquini MC, Giles KE, D'Souza A, Logan BR, Hamadani M, Chhabra S, Dhakal B, Shah N, Sriram D, Horowitz MM, Cole SW.) Blood Adv. 2020 02 11;4(3):467-476 PMID: 32027744 PMCID: PMC7013267 SCOPUS ID: 2-s2.0-85082178004 02/07/2020
Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.

(Badar T, Shah NN.) Curr Treat Options Oncol. 2020 02 05;21(2):16 PMID: 32025828 SCOPUS ID: 2-s2.0-85079049524 02/07/2020
Bispecific chimeric antigen receptor T cell therapy for b cell malignancies and multiple myeloma

(Cronk RJ, Zurko J, Shah NN.) Cancers. September 2020;12(9):1-15 SCOPUS ID: 2-s2.0-85090236837 09/01/2020